The Cochrane database of systematic reviews, (1)(1), CD006586-CD006586 (2008-02-07)
Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. Combined oral contraceptives (COCs), which have both progestin and estrogen, have been examined for their ability to relieve premenstrual symptoms. A COC containing
Climacteric : the journal of the International Menopause Society, 13(1), 22-33 (2009-11-27)
Hormone therapy is effective for the relief of menopausal symptoms. For women with a uterus, addition of a progestogen is required to protect the endometrium. However, synthetic progestins differ in certain pharmacological characteristics that may have implications for clinical practice.
Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, possibly associated with changes in blood pressure and endothelial function. The objective was to evaluate the impact of COC containing 20 mcg of ethinylestradiol (EE) and 3
Climacteric : the journal of the International Menopause Society, 10 Suppl 1, 11-18 (2007-03-17)
Drospirenone is a unique progestogen derived from 17alpha-spirolactone, with a pharmacologic profile very similar to that of endogenous progesterone. In contrast with other available progestins, drospirenone is a progestogen with aldosterone receptor antagonism (PARA) through its affinity for the mineralocorticoid
The Annals of pharmacotherapy, 44(5), 898-903 (2010-04-08)
To review primary literature regarding the risk of venous thromboembolism (VTE) in users of combined oral contraceptives (COCs) containing drospirenone compared to COCs containing other progestins. A literature search of MEDLINE and EMBASE (1950-January 2010) was conducted using the following
